MX366804B - Translocaciones de la r-espondina y sus metodos de uso. - Google Patents

Translocaciones de la r-espondina y sus metodos de uso.

Info

Publication number
MX366804B
MX366804B MX2014009512A MX2014009512A MX366804B MX 366804 B MX366804 B MX 366804B MX 2014009512 A MX2014009512 A MX 2014009512A MX 2014009512 A MX2014009512 A MX 2014009512A MX 366804 B MX366804 B MX 366804B
Authority
MX
Mexico
Prior art keywords
methods
same
spondin
translocations
spondin translocations
Prior art date
Application number
MX2014009512A
Other languages
English (en)
Other versions
MX2014009512A (es
Inventor
Somasekar Seshagiri
Zora Modrusan
Steffen Durinck
Eric William Stawiski
Sauvage Frederic J De
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2014009512A publication Critical patent/MX2014009512A/es
Publication of MX366804B publication Critical patent/MX366804B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Abstract

Se proveen terapias relacionadas con el tratamiento de condiciones patológicas, tales como cáncer.
MX2014009512A 2012-02-11 2013-02-11 Translocaciones de la r-espondina y sus metodos de uso. MX366804B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261597746P 2012-02-11 2012-02-11
US201261674763P 2012-07-23 2012-07-23
PCT/US2013/025525 WO2013120056A1 (en) 2012-02-11 2013-02-11 R-spondin translocations and methods using the same

Publications (2)

Publication Number Publication Date
MX2014009512A MX2014009512A (es) 2014-09-12
MX366804B true MX366804B (es) 2019-07-25

Family

ID=47750060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009512A MX366804B (es) 2012-02-11 2013-02-11 Translocaciones de la r-espondina y sus metodos de uso.

Country Status (16)

Country Link
US (2) US20130209473A1 (es)
EP (1) EP2812350B1 (es)
JP (2) JP6545959B2 (es)
KR (1) KR102148303B1 (es)
CN (2) CN113398268A (es)
AR (1) AR089978A1 (es)
AU (1) AU2013216753B2 (es)
BR (1) BR112014019741A2 (es)
CA (1) CA2862316A1 (es)
HK (1) HK1211037A1 (es)
IL (2) IL233680B (es)
MX (1) MX366804B (es)
RU (1) RU2014133069A (es)
SG (1) SG11201404703WA (es)
WO (1) WO2013120056A1 (es)
ZA (1) ZA201406620B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158758B2 (en) 2007-07-02 2012-04-17 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
RU2014101669A (ru) 2011-07-15 2015-09-20 Онкомед Фармасьютикалс, Инк. Агенты, связывающие белки r-спондины (rspo), и способы их применения
MX2015000565A (es) 2012-07-13 2015-04-10 Oncomed Pharm Inc Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
CA2888455C (en) 2012-10-16 2021-11-09 Dna Polymerase Technology, Inc. Inhibition-resistant polymerases
MX2016004802A (es) 2013-10-18 2016-07-18 Genentech Inc Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
WO2015195949A2 (en) 2014-06-18 2015-12-23 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
JP6673923B2 (ja) * 2014-09-16 2020-03-25 ジェンザイム・コーポレーション ミオシリン（ｍｙｏｃ）緑内障を処置するためのアデノ随伴ウイルスベクター
MA40574A (fr) 2014-09-16 2016-03-24 Oncomed Pharm Inc Traitement de maladies fibrotiques
US9777052B2 (en) 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use
WO2016183294A1 (en) 2015-05-12 2016-11-17 Dna Polymerase Technology, Inc. Mutant polymerases and uses thereof
JP2018522062A (ja) * 2015-05-26 2018-08-09 キュアジェニックス コーポレーション 腫瘍バイオマーカー及びその使用
WO2017095918A2 (en) * 2015-12-01 2017-06-08 Oncomed Pharmaceuticals, Inc. Methods for treating cancer using rspo3 antagonists
WO2017106790A1 (en) 2015-12-18 2017-06-22 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
US20170319688A1 (en) 2016-04-14 2017-11-09 Genentech, Inc. Anti-rspo3 antibodies and methods of use
US11104953B2 (en) 2016-05-13 2021-08-31 Children's Hospital Medical Center Septic shock endotyping strategy and mortality risk for clinical application
CA3019932A1 (en) * 2016-05-13 2017-11-16 Children's Hospital Medical Center Simplification of a septic shock endotyping strategy for clinical application
US11858980B2 (en) 2016-08-02 2024-01-02 Visterra, Inc. Engineered polypeptides and uses thereof
US10815534B2 (en) * 2016-08-23 2020-10-27 Mayo Foundation For Medical Education And Research Methods and materials for treating estrogen receptor positive breast cancer
US20190262371A1 (en) * 2016-10-20 2019-08-29 The Regents Of The University Of California Methods and composition for the treatment of rna viral infections
EP3559264A4 (en) * 2016-12-21 2020-08-12 Agency for Science, Technology and Research MALIGNANT DISORDER IDENTIFICATION KIT AND ITS USES
WO2021070739A1 (ja) * 2019-10-08 2021-04-15 国立大学法人 東京大学 分析装置、分析方法及びプログラム
US11877021B2 (en) 2019-12-27 2024-01-16 Nippon Hoso Kyokai Transmitting device and receiving device
CN113957075B (zh) * 2021-11-22 2023-04-07 百世诺(北京)医学检验实验室有限公司 突变的遗传性心律失常基因及其应用
CN114107482A (zh) * 2021-11-29 2022-03-01 百世诺(北京)医学检验实验室有限公司 肺动脉高压突变基因及其应用

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3590766C2 (es) 1985-03-30 1991-01-10 Marc Genf/Geneve Ch Ballivet
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69130831T2 (de) 1990-11-21 1999-09-16 Iterex Pharma Lp Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1995034683A1 (en) 1994-06-10 1995-12-21 Symbiotech, Inc. Method of detecting compounds utilizing genetically modified lambdoid bacteriophage
US5627024A (en) 1994-08-05 1997-05-06 The Scripps Research Institute Lambdoid bacteriophage vectors for expression and display of foreign proteins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997009446A1 (en) 1995-09-07 1997-03-13 Novo Nordisk A/S Phage display for detergent enzyme activity
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP0904541B1 (en) 1996-03-20 2004-10-06 Dyax Corp. PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (tPA)
AU734638B2 (en) 1996-06-06 2001-06-21 Lajolla Pharmaceutical Company aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
AU735015B2 (en) 1996-06-10 2001-06-28 Scripps Research Institute, The Use of substrate subtraction libraries to distinguish enzyme specificities
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
WO1998014277A1 (en) 1996-10-04 1998-04-09 Whatman, Inc. Device and method for simultaneous multiple chemical syntheses
DE69718341T2 (de) 1996-10-08 2003-10-30 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
EP0938497B1 (en) 1996-11-06 2007-02-28 Genentech, Inc. Constrained helical peptides and methods of making same
IL119587A (en) 1996-11-07 2000-12-06 Univ Ramot Method of preparing and for obtaining bimolecular interactions
IL119586A (en) 1996-11-07 2001-09-13 Univ Ramot Discontinuous library of a single biological unit and a method for its preparation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6387657B1 (en) 1997-10-29 2002-05-14 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
PT1034298E (pt) 1997-12-05 2012-02-03 Scripps Research Inst Humanização de anticorpo murino
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
EP1141708A1 (en) 1998-12-28 2001-10-10 Sunesis Pharmaceuticals Inc. Identifying small organic molecule ligands for binding
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US7005499B1 (en) 1999-11-18 2006-02-28 Genentech, Inc. Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
ES2323220T3 (es) 2000-01-13 2009-07-09 Genentech, Inc. Polipeptidos humanos stra6.
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
ES2651952T3 (es) 2000-10-06 2018-01-30 Kyowa Hakko Kirin Co., Ltd. Células que producen unas composiciones de anticuerpo
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
WO2002033085A2 (en) 2000-10-16 2002-04-25 Genentech, Inc. Wisp polypeptides and therapeutical applications thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236015A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition
EP1500698B1 (en) 2002-04-09 2011-03-30 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
WO2003085107A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules à génome modifié
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7455834B2 (en) 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20060292150A1 (en) 2003-09-11 2006-12-28 Luc Desnoyers Methods of using wisp antagonists
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk HYBRID PROTEIN COMPOSITION
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
EP2093298A3 (en) 2003-10-10 2009-09-23 Deutsches Krebsforschungszentrum Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins)
EP1692182B1 (en) 2003-11-05 2010-04-07 Roche Glycart AG Cd20 antibodies with increased fc receptor binding affinity and effector function
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
ES2403055T3 (es) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anticuerpos anti-P-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20090220495A1 (en) * 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
JP2009502737A (ja) * 2005-07-26 2009-01-29 キリンファーマ株式会社 Ｒ−スポンジンを含有する抗腫瘍薬
US7541431B2 (en) 2005-09-07 2009-06-02 Maine Medical Center Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007121147A2 (en) 2006-04-10 2007-10-25 Genentech, Inc. Disheveled pdz modulators
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
JP2008044926A (ja) 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
CL2007002609A1 (es) 2006-09-08 2008-04-18 Genentech Inc Antagonista de wnt que comprende un componente del dominio frizzled y un dominio fc; secuencia de acidos nucleicos que lo codifica; composicion que lo comprende; y su uso para tratar trastornos de proliferacion celular.
US8088374B2 (en) * 2006-10-20 2012-01-03 Deutsches Krebsforschungszentrum Stiftung Des Offenlichen Rechts Methods for inhibition of angiogenesis and vasculogenesis via rspondin antagonists
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US8158758B2 (en) 2007-07-02 2012-04-17 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
CA2709847C (en) 2008-01-07 2018-07-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2977060A1 (en) 2009-12-23 2016-01-27 Deutsches Krebsforschungszentrum Receptors of rspo2 and rspo3
NZ602040A (en) 2010-03-24 2014-12-24 Genentech Inc Anti-lrp6 antibodies

Also Published As

Publication number Publication date
BR112014019741A2 (pt) 2020-12-22
KR20140130461A (ko) 2014-11-10
AU2013216753A1 (en) 2014-08-14
ZA201406620B (en) 2016-08-31
AU2013216753B2 (en) 2017-09-21
CN113398268A (zh) 2021-09-17
JP6545959B2 (ja) 2019-07-17
HK1211037A1 (en) 2016-05-13
KR102148303B1 (ko) 2020-08-26
RU2014133069A (ru) 2016-04-10
IL267560A (en) 2019-08-29
AR089978A1 (es) 2014-10-01
EP2812350B1 (en) 2019-04-03
EP2812350A1 (en) 2014-12-17
US20130209473A1 (en) 2013-08-15
SG11201404703WA (en) 2014-09-26
IL233680A0 (en) 2014-09-30
MX2014009512A (es) 2014-09-12
WO2013120056A1 (en) 2013-08-15
IL233680B (en) 2020-02-27
CA2862316A1 (en) 2013-08-15
JP2018021068A (ja) 2018-02-08
CN104718220A (zh) 2015-06-17
US20210025008A1 (en) 2021-01-28
JP2015513529A (ja) 2015-05-14

Similar Documents

Publication Publication Date Title
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
EA201590987A1 (ru) Соединения и способы их применения
EP3027192A4 (en) Methods for the treatment of solid tumors
EA201400178A1 (ru) Лечение рака молочной железы
EA201590997A1 (ru) Соединения и способы их применения
IL238177A0 (en) Methods and preparations for the treatment of cancer
MX2015011428A (es) Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
TW201611843A (en) Methods of treatment with arginine deiminase
EP3060680A4 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
EP2996721A4 (en) Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
MX2019010098A (es) Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico.
PH12014502032A1 (en) Treatment of brain cancer
PL3089749T3 (pl) Preparaty skojarzone do leczenia raka
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
IN2014MN01945A (es)
EP3004396A4 (en) Methods and compositions for the treatment of cancer
EP3008212A4 (en) Methods of treatment of cancer
IN2014MN01944A (es)
HK1223547A1 (zh) 癌症治療方法
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB2528604A (en) Modulation of asymmetric proliferation
EP3016948B8 (en) 2-acylaminothiazoles for the treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration